Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Boundless Bio: designing cancer therapies around extrachromosomal DNA

Boundless Bio launches with $46M series A to tackle unexplored extrachromosomal DNA target space in cancer

With a $46.4 million series A round led by Arch Venture Partners and City Hill Ventures, Boundless Bio is opening up a new target space in cancer by combining a commercially explored concept in tumor biology with President and CEO Zach Hornby’s expertise in precision medicine.

The San Diego-based company was founded around the idea that extrachromosomal DNA (ecDNA) is behind

Read the full 608 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers